EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy.
Presentation details: Title: Triple Combination of Amantadine, Ribavirin and Oseltamivir Restores In Vitro Activity of Antiviral Drugs against Resistant Influenza Viruses Date/Time: Sunday, Sep 13, 2009, 10:45 AM -11:00 AM Session: 064-Respiratory Viruses and Influenza Sunday, Sep 13, 2009, 8:30 AM -11:00 AM Abstract Number: V-537b Location: Marriott Salon 9 Authors: J. T. NGUYEN (1), J. HOOPES (2), D. SMEE (2), M. LE (1), A. PATICK (1), M. DE JONG (3), G. WENT (1), D. FAIX (4), P. BLAIR (4), M. PRICHARD (5); (1) Adamas Pharmaceuticals, Emeryville, CA, (2) Utah State Univ., Logan, UT, (3) Amsterdam Med. Ctr., Amsterdam, Netherlands, (4) Naval Health Research Center, San Diego, CA, (5) Univ. of Alabama, Birmingham, AL.
Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunct
|SOURCE Adamas Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved